DrugPatentWatch Database Preview
FORTESTA Drug Profile
see a sample report or, see our see our flat-rate plans
When do Fortesta patents expire, and when can generic versions of Fortesta launch?
Fortesta is a drug marketed by Endo Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-one patent family members in sixteen countries.
The generic ingredient in FORTESTA is testosterone. There are sixty-five drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
Summary for FORTESTA
| International Patents: | 21 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 65 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,214 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for FORTESTA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FORTESTA |
| DailyMed Link: | FORTESTA at DailyMed |
Pharmacology for FORTESTA
| Ingredient-type | Androstanes |
| Drug Class | Androgen |
| Mechanism of Action | Androgen Receptor Agonists |
Medical Subject Heading (MeSH) Categories for FORTESTA
Synonyms for FORTESTA
| (+-)-8-iso-testosterone |
| (+-)-retrotestosterone |
| (+-)-testosterone |
| (+)-testosterone |
| (17?)-17-Hydroxyandrost-4-en-3-one |
| (17b)-17-hydroxy-androst-4-en-3-one |
| (17beta)-17-Hydroxyandrost-4-en-3-one |
| (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one |
| (1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-6-EN-5-ONE |
| (8alpha,10alpha,13alpha,14beta,17alpha)-17-hydroxyandrost-4-en-3-one |
| (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one |
| (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
| (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one |
| 003T654 |
| 1050678-68-6 |
| 13-iso-testosterone |
| 17-.beta.-Hydroxyandrost-4-en-3-one |
| 17-beta-Hydroxy-delta(sup 4)-androsten-3-one |
| 17-beta-Hydroxyandrost-4-en-3-one |
| 17-Hydroxy-(17-beta)-androst-4-en-3-one |
| 17-Hydroxy-(17beta)-androst-4-en-3-one |
| 17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one |
| 17-Hydroxy-4-androsten-3-one |
| 17-hydroxy-androst-4-en-3-one |
| 17-hydroxy-D4-androsten-3-one |
| 17-Hydroxyandrost-4-en-3-one, (17.beta.)- |
| 17.beta.-Hydroxy-.DELTA.4-androsten-3-one |
| 17.beta.-Testosterone |
| 17a-hydroxy-(13a)-androst-4-en-3-one |
| 17a-hydroxy-13a-androst-4-en-3-one |
| 17a-hydroxy-14b-androst-4-en-3-one |
| 17a-hydroxy-androst-4-en-3-one |
| 17b-hydroxy-(10a)-androst-4-en-3-one |
| 17b-hydroxy-(13a)-androst-4-en-3-one |
| 17b-hydroxy-(8a,10a)-androst-4-en-3-one |
| 17b-hydroxy-(8a)-androst-4-en-3-one |
| 17b-hydroxy-(9b,10a)-androst-4-en-3-one |
| 17b-hydroxy-(9b)-androst-4-en-3-one |
| 17b-hydroxy-13a-androst-4-en-3-one |
| 17b-hydroxy-4-androsten-3-one |
| 17b-hydroxy-8a-androst-4-en-3-one |
| 17b-Hydroxy-androst-4-en-3-on |
| 17b-hydroxy-androst-4-en-3-one |
| 17b-Hydroxy-D4-androsten-3-one |
| 17b-Hydroxyandrost-4-ene-3-one |
| 17b-Testosterone |
| 17beta-Hydroxy-3-oxo-4-androstene |
| 17beta-Hydroxy-4-androsten-3-one |
| 17beta-hydroxy-4-androsten-3one |
| 17beta-Hydroxy-delta(sup4)-androsten-3-one |
| 17beta-Hydroxyandrost-4-en-3-one |
| 17beta-Hydroxyandrost-4-ene-3-one |
| 17beta-testosterone |
| 1i37 |
| 3kdm |
| 3XMK78S47O |
| 4-androsten-17-ol-3-one |
| 4-Androsten-17.beta.-ol-3-one |
| 4-Androsten-17beta-ol-3-one |
| 4-Androsten-3-one-17.beta.-ol |
| 4-Androsten-3-one-17b-ol |
| 4-Androsten-3-one, 17b-hydroxy- |
| 4-androstene-17beta-ol-3-one |
| 58-22-0 |
| 7-beta-Hydroxyandrost-4-en-3-one |
| 8-iso-testosterone |
| 9b-testosterone |
| 9b,10a-testosterone |
| AA 2500 |
| AB00973630-03 |
| AC-14899 |
| AC1L1LM0 |
| AK405367 |
| AKOS015894897 |
| AN-23597 |
| Andro 100 |
| Androderm |
| Androderm (TN) |
| Androderm, Delatestryl |
| AndroGel |
| Androgel (TN) |
| Androgel 1.62% |
| Androgel 1% |
| Androlin |
| Andronaq |
| Andronate 100 |
| Andronate 200 |
| Andropatch |
| Andropository 200 |
| Androsorb |
| Androst-4-en-17b-ol-3-one |
| Androst-4-en-17beta-ol-3-one |
| Androst-4-en-3-on-17B-ol |
| Androst-4-en-3-one, 17-beta-hydroxy- |
| Androst-4-en-3-one, 17-hydroxy-, (17-beta)- |
| Androst-4-en-3-one, 17-hydroxy-, (17.beta.)- |
| Androst-4-en-3-one, 17-hydroxy-, (17b)- |
| Androst-4-en-3-one, 17-hydroxy-, (17beta)- |
| Androst-4-en-3-one, 17-hydroxy, (17.beta.)- |
| Androst-4-en-3-one, 17beta-hydroxy- |
| Androst-4-ene-17b-ol-3-one |
| Andrusol |
| Andryl 200 |
| Axiron |
| Axiron (TN) |
| B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E |
| BC208298 |
| BDBM8885 |
| beta testosterone |
| BIDD:ER0555 |
| BIM-0061761.0001 |
| Bio-0678 |
| Bio-T-Gel |
| BT000432 |
| C-18145 |
| C00535 |
| CAS-58-22-0 |
| CCG-101189 |
| CCRIS 574 |
| CDB 111C |
| CHEBI:17347 |
| CHEMBL386630 |
| CMC_13449 |
| COL 1621 |
| CompleoTRT |
| component of Di-Genik (Salt/Mix) |
| component of Di-Met (Salt/Mix) |
| component of Duogen (Salt/Mix) |
| component of Intrinsa (Salt/Mix) |
| component of Mal-O-Fem (Salt/Mix) |
| component of Tostrex (Salt/Mix) |
| CP 601B |
| CPD000058344 |
| Cristerona T |
| Cristerone T |
| CS-1415 |
| D00075 |
| D06XMU |
| D4-Androsten-17b-ol-3-one |
| DB00624 |
| delta(sup 4)-Androsten-17(beta)-ol-3-one |
| delta4-androsten-17b-ol-3-one |
| delta4-Androsten-17beta-ol-3-one |
| DSSTox_CID_2371 |
| DSSTox_GSID_22371 |
| DSSTox_RID_76563 |
| DTXSID8022371 |
| EINECS 200-370-5 |
| Epitestosteron |
| Epitope ID:135865 |
| Everone 200 |
| Geno-cristaux gremy |
| GTPL2858 |
| Halotensin |
| HMS2052N11 |
| HMS2272B03 |
| HMS2272P03 |
| Homosteron |
| Homosterone |
| HSDB 3398 |
| HY-15554A |
| Intrinsa |
| LibiGel |
| LMST02020002 |
| LS-148813 |
| Lumitestosteron |
| Malerone |
| Malestrone (amps) |
| Malogen in Oil |
| Malogen, aquaspension injection |
| MCULE-1294118086 |
| Mertestate |
| MLS000563091 |
| MLS001032098 |
| MLS001306401 |
| MLS001424262 |
| MLS002174283 |
| mpp10 |
| MUMGGOZAMZWBJJ-DYKIIFRCSA-N |
| Nasobol |
| NC00439 |
| NCGC00091018-01 |
| NCGC00258243-01 |
| Neo-Hombreol F |
| Neo-testis |
| Neotestis |
| NSC 9700 |
| Oreton |
| Oreton F |
| Oreton-F |
| Orquisteron |
| Perandren |
| Percutacrine androgenique |
| PL000185 |
| Primotest |
| Primoteston |
| Q-101251 |
| rac-17b-hydroxy-(13a)androst-4-en-3-one |
| rac-17b-hydroxy-(8a)-androst-4-en-3-one |
| rac-17b-hydroxy-(9b,10a)androst-4-en-3-one |
| rac-17b-hydroxy-androst-4-en-3-one |
| RB3046 |
| Relibra |
| RP29985 |
| S00309 |
| SC-15109 |
| Scheinpharm Testone-Cyp |
| SCHEMBL8452 |
| SMR000058344 |
| SMR001261453 |
| Striant |
| Striant (TN) |
| Sustanon |
| Sustanone |
| Sustason 250 |
| Synandrol F |
| T-Cypionate |
| Teslen |
| Testamone 100 |
| Testandrone |
| Testaqua |
| Testiculosterone |
| Testim |
| Testim (TN) |
| Testobase |
| Testoderm |
| Testoderm Tts |
| Testogel |
| Testoject-50 |
| Testolin |
| Testopel Pellets |
| Testopropon |
| Testosteroid |
| Testosteron |
| Testosterona |
| Testosterona [INN-Spanish] |
| testosterone |
| Testosterone (JAN/USP) |
| Testosterone [Androgenic steroids, anabolic] |
| Testosterone [INN:BAN] |
| Testosterone [USP:INN:BAN] |
| Testosterone 1.0 mg/ml in Acetonitrile |
| Testosterone 100 microg/mL in Acetonitrile |
| Testosterone and its esters |
| Testosterone for impurity D identification, European Pharmacopoeia (EP) Reference Standard |
| Testosterone for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Testosterone hydrate |
| Testosterone solution |
| Testosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, drug standard |
| Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material |
| Testosterone, >=98% |
| Testosterone, 1 |
| Testosterone, cell culture tested |
| Testosterone, European Pharmacopoeia (EP) Reference Standard |
| Testosterone, purum, >=99.0% (HPLC) |
| Testosterone, VETRANAL(TM), analytical standard |
| Testosterone; 4-Androsten-17?-ol-3-one; 17?-Hydroxy-4-androsten-3-one |
| Testosteronum |
| Testosteronum [INN-Latin] |
| Testostosterone |
| Testoviron |
| Testoviron Schering |
| Testoviron T |
| Testred Cypionate 200 |
| Testrin-P.A |
| Testro AQ |
| Testrone |
| Testryl |
| Tostrelle |
| Tostrex |
| Tox21_200689 |
| trans-Testosterone |
| UNII-3XMK78S47O |
| Viatrel |
| Virilon IM |
| Virormone |
| Virosterone |
| W-5033 |
| ZINC118912393 |
US Patents and Regulatory Information for FORTESTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Pharms | FORTESTA | testosterone | GEL, METERED;TRANSDERMAL | 021463-001 | Dec 29, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Endo Pharms | FORTESTA | testosterone | GEL, METERED;TRANSDERMAL | 021463-001 | Dec 29, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for FORTESTA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 10 mg/actuation | ➤ Subscribe | ➤ Sign Up |
Non-Orange Book US Patents for FORTESTA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,157,097 | Penetration enhancing and irritation reducing systems | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for FORTESTA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9924041 | ➤ Sign Up |
| New Zealand | 504423 | ➤ Sign Up |
| Spain | 2318233 | ➤ Sign Up |
| Australia | 1313299 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
